Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity Trial of Boost-2867 SARS-CoV-2 Booster Vaccine
NCT07221162Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial in coronavirus disease 2019 (COVID-19) (7 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of abnormal clinical safety laboratory adverse events at Day 8, Occurrence of adverse events of special interest at 6 months and 7 more. Started Dec 2025; status: active, not recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07221162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221162.